KSQ Therapeutics, Inc. announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, which will evaluate safety and preliminary efficacy in advanced solid tumors.
Anna Truppel-Hartmann has over 15 years of experience in the pharmaceutical and biotechnology sectors. She earned a medical degree in Switzerland and has expertise in clinical development, medical affairs, patient engagement, and talent development.
Elizabeth Twomey-Gansler has served as Head of Human Resources at KSQ Therapeutics since April 2019. Previously, Elizabeth worked in executive search recruiting physicians and clinical development professionals for life-science companies.
Micah Benson joined KSQ at its founding and built its Immuno-Oncology and Autoimmunity efforts. Micah co-invented KSQ’s Immune CRISPRomics platform, and the work led to the discovery of SOCS1 and Regnase-1 and the development of KSQ’s eTIL programs.
KSQ conducts genome-wide CRISPR/Cas9 functional genomic screens across cancer models and immune cell types to identify therapeutic targets. The company calls this approach CRISPRomics.
